Brief: NRX Pharmaceuticals Reports First Quarter 2023 Financial Results
16/05/2023 11:49
May 16 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
* NRX PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.16
* NRX PHARMACEUTICALS - EVALUATING OPERATIONAL EFFICIENCIES
ASSOCIATED WITH COMPLETION OF MANUFACTURING ACTIVITIES TO EXTEND
CASH RUNWAY
* NRX PHARMACEUTICALS - CASH, CASH EQUIVALENTS AT END OF Q1
EXPECTED TO FUND OPERATIONS THROUGH EXPECTED DELIVERY OF DATA IN
PHASE 2B/3 TRIAL OF NRX-101
Source text for Eikon: ID:nPnjMr5za
Further company coverage: NRXP.O
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview